

No.	Category	Modality, etc.	Title2	Summary3
1	Neurological disorders	Protein	<b>GFRα1: A First-in-Class Lead for Functional CNS and PNS Nerve Regeneration</b>	We identified GFRα1 as a first-in-class lead for CNS and PNS axonal regeneration. In vivo studies demonstrate accelerated recovery of sensory and motor functions by bypassing the inhibitory environment. Leveraging our proprietary evaluation system and RNA-seq data, we seek partners to advance this novel regenerative therapy and explore broader drug discovery applications in the nerve repair space.
2	Neurological disorders	Peptide	<b>p3-AIcβ9-19: A Primate-Validated, Brain-Penetrant Mitochondrial Activator for AD</b>	We have developed an endogenous 11-amino acid peptide that restores neuronal viability by activating mitochondrial complex I. Validated in monkeys via PET imaging, it crosses the blood-brain barrier through needle-free transdermal delivery. We seek strategic partners for FIH trials to position this as a safe, disease-modifying intervention for early-stage Alzheimer's Disease.
3	Neurological disorders	RNA	<b>Targeted RNA Chaperones: A Precise Mechanism to Protect Motor Neurons in ALS</b>	We identified short RNA repeats that act as molecular chaperones to suppress pathological TDP-43 aggregation without affecting physiological transcription. This approach restores proteostasis and reduces cytotoxicity in neuronal models. We are seeking collaborators for in vivo studies to advance this high-specificity alternative to conventional antisense therapies for ALS and FTLTLD.
4	Neurological disorders	Small Molecule · Antibody etc.	<b>NET Inhibitors: Accelerating Acute Nerve Repair via the MIF/CXCR4 Axis</b>	Our technology promotes nerve regeneration by inhibiting Neutrophil Extracellular Traps (NETs) immediately post-injury. Data demonstrates that targeting the MIF/CXCR4 axis significantly accelerates macrophage-driven myelin clearance and axonal growth. We seek partners to develop this acute intervention strategy as a novel recovery approach for peripheral nerve trauma and Wallerian degeneration.
5	Drug Delivery System	LNP	<b>HSC-Targeted LNPs: A Precision Delivery Platform for Reversing Hepatic Fibrosis</b>	We have engineered a specialized LNP platform with high specificity for activated hepatic stellate cells (HSCs), the drivers of fibrosis. In vivo data demonstrates potent anti-fibrotic efficacy with minimal hepatocyte toxicity. This scalable system is ideal for partners looking to deliver RNA or small molecules for advanced MASH and cirrhosis therapies.
6	Drug Delivery System	LNP	<b>Spleen-Specific LNPs: Optimized Dendritic Cell Delivery for Next-Gen Vaccines</b>	This novel LNP formulation overcomes liver-centric distribution to achieve targeted mRNA delivery to splenic dendritic cells. Preclinical results show robust systemic immune activation and superior tumor protection compared to clinical-grade benchmarks. We seek partners to integrate this high-affinity platform into cancer vaccine or systemic immunotherapy portfolios.
7	Drug Delivery System	LNP	<b>Helper Lipids: A Potency-Boosting Solution for Enhanced Endosomal Escape</b>	Our proprietary helper lipids accelerate intracellular cargo release by promoting efficient membrane fusion. Integration into standard LNP formulations dramatically improves mRNA expression and therapeutic potency. This technology offers a strategic advantage for partners aiming to lower systemic dosing and improve the safety profiles of RNA-based drug candidates.
8	Drug Delivery System	LNP	<b>Novel ζ-Lipids for Cas9 RNP Delivery: 98% Gene Knockout in vivo</b>	We developed optimized ionizable lipids (ζ-lipids) that achieve over 98% reduction in target proteins after a single dose of CRISPR/Cas9 RNP. Validated for high hepatic efficiency and low toxicity, this non-viral platform offers a rapid, safe alternative to viral vectors. We seek partners for the clinical translation of genetic liver disease therapies.
9	DDS	LNP	<b>NK Cell-Specific LNPs: Scalable Genetic Modification for Cold Tumor Therapy</b>	Our specialized LNP platform efficiently introduces RNA into human NK cells with minimal toxicity, offering a scalable alternative to ex vivo viral transduction. This enables transient genetic modification to boost cytotoxicity and persistence in the tumor microenvironment. We seek partners to co-develop this transient modification strategy for T-cell-evading cancers.
10	Drug Delivery System	LNP	<b>Novel Cationic Lipids for Extrahepatic Delivery</b>	Novel LNPs with our original lipids can encapsulate various nucleic acids, including siRNA and mRNA, and achieve superior delivery to the spleen, heart, lungs, and skeletal muscles compared to standard formulations. This platform offers high strategic value for developing next-generation gene therapies and "beyond-liver" RNA therapeutics, providing a versatile tool for tissue-specific targeting and enhanced endosomal escape.
11	Rare diseases	RNA · Gene Therapy	<b>srRNA: A Stable, Vector-Based Alternative for Exon-Skipping Therapies</b>	We developed "srRNA," a programmable scaffold expressed from viral vectors to induce targeted exon skipping. Unlike short-lived ASOs, srRNA provides sustained, low-toxicity therapeutic effects. With validation in muscular dystrophy models, we seek partners interested in developing long-term genetic treatments for Duchenne muscular dystrophy and other splicing disorders.
12	Oncology	Antibody	<b>PIECE Platform Technology targeting Intracellular IL-6 for Tumor Therapeutics</b>	Using our proprietary PIECE platform, we achieved successful intracellular delivery of anti-IL-6 antibodies, targeting the source of pro-tumor signaling. This approach suppresses tumor proliferation and resistance that extracellular antibodies cannot reach. We seek partners to apply this intracellular delivery technology to a wide range of previously unreachable cytosolic targets in oncology.
13	Oncology	Antibody	<b>Anti-IL-34 mAbs: Strategic Add-ons to Overcome Therapeutic Resistance</b>	We developed monoclonal antibodies specific to IL-34 that inhibit binding to CSF-1R, reversing drug resistance in the tumor microenvironment. Preclinical data shows restored efficacy of standard-of-care therapies when combined with our mAb. We seek partners to evaluate this as a strategic combination therapy to prevent or overcome resistance in solid tumors.
14	Oncology	middle-molecule	<b>DCA-Micelles: A Precision Metabolic Radiosensitizer for Local Tumor Control</b>	These self-assembling micelles deliver dichloroacetic acid (DCA) specifically to tumors, increasing their sensitivity to radiotherapy while minimizing systemic toxicity. By modifying tumor metabolism at the site of irradiation, this technology enhances the therapeutic index of radiotherapy. We seek clinical partners to advance this as a promising adjunct therapy for localized resistant cancers.
15	Oncology	Antibody	<b>Alternative MoA Antibodies for ATL and Burkitt Lymphoma</b>	These monoclonal antibodies target adult T-cell leukemia (ATL) via a unique mechanism distinct from Mogamulizumab. Successfully validated in animal models, they inhibit the growth of resistant T-cell lines. We seek oncology partners to position this as a differentiated therapeutic option for refractory lymphoma.
16	Oncology	Small Molecule / Peptide	<b>Sequence-Specific BATF-IRF4-JUN Binding Assay for High-Throughput Screening</b>	This asset provides a quantitative assay measuring sequence-specific cooperative binding of the IRF4/BATF3/JUN transcriptional complex to AICE DNA motifs. The system enables identification of modulators that disrupt this oncogenic transcriptional network, creating opportunities to explore differentiated therapeutic strategies in T-cell malignancies, including adult T-cell leukemia/lymphoma, while maintaining clear specificity over conventional AP-1 assays.
17	Oncology/Inflammatory diseases	Small Molecule	<b>Epigenetic Modulator for Refractory GVHD and IBD</b>	Our asset presents a novel drug target for refractory GVHD and IBD, designed to prevent inflammatory flares and disease aggravation. By modulating specific pathways identified from multiple candidates, it erases the "inflammatory memory" in tissue stem cells. This breakthrough approach suppresses chronic hyper-responsiveness and epithelial apoptosis, significantly improving survival and clinical stability in vivo.
18	Immunology	Small Molecule	<b>Next-Gen STING Agonists: Converting Cold Tumors via Potent Systemic Activation</b>	Our novel lipidated STING agonists demonstrate enhanced cytokine induction relative to benchmark compounds. Designed for high membrane permeability and systemic stability, these compounds induce strong anti-tumor responses in breast cancer models. We seek partners for clinical development, particularly for use with immune checkpoint inhibitors.
19	Immunology	Peptide	<b>STAP-1 Peptides: Selective T-Cell Modulation for Precision Autoimmune Therapy</b>	We developed inhibitory peptides targeting the STAP-1 scaffold to selectively block T-cell overactivation. Validated in multiple sclerosis and asthma models, these peptides avoid broad immunosuppression while achieving significant clinical improvement. We seek partners to co-develop this precision immunomodulator for T-cell-driven autoimmune and allergic inflammatory diseases.
20	Immunology	Cell Therapy	<b>CD28-NKG2D Chimeric Receptors: Overcoming Exhaustion in Solid Tumor CAR-T</b>	This technology incorporates a novel chimeric receptor to boost the cytotoxicity and longevity of CAR-T cells, even in tumors with low antigen density. In vivo persistence is significantly enhanced through powerful co-stimulation. We seek immunotherapy partners to advance this strategy for more effective solid tumor treatment.
21	Inflammatory diseases	nucleic acid	<b>Meflin: A Novel Biomarker and Therapeutic Target for Systemic Inflammation</b>	Our research identifies Meflin as a novel TNF receptor ligand and potent activator of the NF-κB pathway. siRNA or antibody-mediated depletion successfully suppresses chronic inflammation in systemic models. We seek partners to develop Meflin-targeted therapies and high-sensitivity biomarkers for rheumatoid arthritis and other chronic inflammatory disorders.
22	Cirrhosis	Cell	<b>IL-34-Induced Macrophages: Autologous Cell Therapy for Advanced Liver Cirrhosis</b>	This regenerative therapy uses autologous macrophages differentiated with IL-34, showing superior anti-fibrotic activity compared to standard CSF-1-induced cells. Successfully validated in human-derived cell models, it offers a transplantation-free alternative for cirrhosis. We seek clinical partners for the development of this personalized, non-immunosuppressive cell therapy.

No.	Category	Modality, etc.	Title2	Summary3
23	Diabetes	Small Molecule	<b>Resolvin E3 Indoles: A Pro-Resolving Approach for Insulin Resistance</b>	We synthesized stable indole derivatives of Resolvin E3 that effectively restore metabolic homeostasis and insulin sensitivity in diabetic models. Unlike current blockers, this pro-resolving approach enhances glucose uptake in adipocytes without detectable adverse effects in preclinical studies. We seek strategic partners to advance this novel metabolic regulator for Type 2 Diabetes.
24	Osteoporosis	Small Molecule	<b>Syk Inhibitors: A Safety Bridge for Post-Denosumab Transition in Osteoporosis</b>	This repurposing candidate addresses the clinical crisis of rebound bone resorption following anti-RANKL antibody discontinuation. By targeting the hyperactive DAP12/TREM2-Syk pathway, the therapy prevents rapid bone density loss and fracture risk. We seek partners to commercialize this vital transition therapy for long-term osteoporosis management.
25	Ophthalmology	Peptide	<b>BDNF-Inducing Peptides: A Neuroprotective Approach for Glaucoma Treatment, Complementing IOP-lowering therapy</b>	Our novel peptides restore deficient BDNF levels by promoting endogenous secretion, protecting retinal ganglion cells from apoptosis. This neuroprotective mechanism complements standard pressure-lowering treatments to halt vision loss. We seek partners to develop this as a comprehensive strategy for preserving neural function in glaucomatous eyes.
26	Dermatology	Small Molecule	<b>Selective Senolytics: Removing Senescent Cells to Reverse UV-Induced Skin Aging</b>	This topical agent selectively removes senescent melanocytes, suppressing chronic SASP-driven inflammation and preventing malignant transformation. Validated for its ability to attenuate age-related skin pathologies, it offers a potent therapy for both cosmetic photoaging and clinical skin diseases. We seek partners for the dermatological commercialization of this agent.
27	Infectious diseases	Antibody	<b>Neutralizing mAbs for Marburg Virus: High-Potency Outbreak Control Tools</b>	We have developed a suite of monoclonal antibodies with neutralizing activity against Marburg and Ravn viruses that meets or exceeds current benchmarks. These mAbs target conserved glycoprotein epitopes, ensuring robust efficacy during lethal outbreaks. We seek biodefense or infectious disease partners for rapid clinical development and outbreak response planning.
28	Infectious diseases	Antibody	<b>Universal Pan-Species Ebola Antibodies: A Cross-Neutralizing Therapeutic Lead</b>	This monoclonal antibody effectively inhibits cellular entry for all known Ebolavirus species by targeting a highly conserved internal fusion loop. Preclinical data confirms protective efficacy in vivo, making this a first-in-class candidate for universal Ebola intervention. We seek partners for global clinical positioning and stockpile development.
29	Infectious diseases	Peptide	<b>Nemuri-Derived Peptides: A New Line of Defense Against MDR Bacterial Pathogens</b>	Derived from the <i>Drosophila</i> "Nemuri" protein, these antibacterial fragments exert potent effects against multi-drug resistant (MDR) strains via a novel mechanism. They demonstrate low human cytotoxicity and high stability. We seek partners to develop these peptides for hospital-acquired infections and persistent bacterial pathogens.
30	Infectious diseases	Small Molecule	<b>2-thiouridine (s2U): A Broad-Spectrum Antiviral for Positive-Strand RNA Viruses</b>	This asset features a nucleoside analog that targets viral RNA-dependent RNA polymerase, inhibiting replication across various flaviviruses. Preclinical data shows a significant improvement in survival rates for dengue-infected models. We seek partners to develop this as a versatile antiviral for global infectious disease management.
31	Protein expression	Vector	<b>Enhanced Mammalian Cell Vectors: High-Yield Production of Bio-Active Proteins</b>	These novel expression vectors impart a high-level production capacity for foreign proteins requiring mammalian-specific folding and glycosylation. This platform optimizes the manufacturing of clinical biologics that are inadequate when produced in yeast or bacteria. We seek biomanufacturing partners to scale this production-boosting system.
32	Peptide Technology	Peptide	<b>Micro-Scale SAR Platform: Rapid Structure-Optimization for Peptide Leads</b>	This technology utilizes a novel amino acid to enable scanning and site-selective modification of peptide sequences on a minute scale. By slashing time and costs for library synthesis, it accelerates the discovery of high-affinity leads. We seek peptide-focused partners to integrate this platform into their early-stage drug discovery pipelines.
33	Peptide Technology	Peptide	<b>Nonribosomal Peptide Cyclases: A High-Throughput Engine for Cyclic Peptide Discovery</b>	This platform utilizes nonribosomal enzymes to synthesize massive macrocyclic peptide libraries with high efficiency and purity. Capable of producing 10,000+ variants annually, it provides a vast chemical space for drug discovery. We seek partners looking to enhance their hit-to-lead pipelines for peptide therapeutics.
34	Mitochondrial diseases	Genome editing technology	<b>MITO-Porter &amp; CRISPR/Cas9: An Advanced Platform for Mitochondrial Gene Editing</b>	The MITO-Porter system delivers CRISPR/Cas9 RNPs directly into mitochondria, overcoming the double-membrane barrier. Validated in MELAS patient cells, this system can precisely remove mutated genes. We seek partners to develop a novel mitochondrial gene-editing strategy for mitochondrial genetic diseases and organelle-specific pathologies.
35	Experimental model animals	Mice	<b>Bioluminescent BLI Mice: Real-Time evaluation for Reproductive Toxicity</b>	This genetically modified mouse model enables non-invasive, temporal evaluation of spermatogenesis and drug effects on fertility via bioluminescence. It offers a more ethical, efficient, and quantitative alternative to traditional toxicology endpoints. We seek CRO or pharma partners for safety assessment tool integration.
36	Animal health	Antibody	<b>Canine Anti-PD-L1: A Checkpoint Inhibitor Candidate for Veterinary Oncology</b>	This canine-specific anti-PD-L1 antibody is designed for high compatibility and repeated administration in pet dogs. Already registered in major markets, it represents a leading product for the booming companion animal oncology sector. We seek veterinary pharma partners for global distribution and brand expansion.
37	Animal health	Antibody	<b>A Novel Anti-Feline PD-L1 Antibody as a Companion Diagnostic for Feline Cancer Immunotherapy</b>	We have developed a novel anti-feline PD-L1 monoclonal antibody (clone CL1Mab-7) with high specificity for immunohistochemical staining. The antibody demonstrates strong reactivity across multiple tumor types, including mammary adenocarcinoma, and may serve as a companion diagnostic tool to identify candidates for PD-1/PD-L1 blockade therapy. This asset addresses an unmet need in veterinary oncology.
38	Diagnostics	Antibody	<b>IgA N-Glycan Markers: A Non-Invasive Diagnostic Tool for MASH Fibrosis Stages</b>	We identified serum IgA-bound glycans that correlate accurately with liver fibrosis progression in MASH patients. This blood-based test offers a reliable alternative to invasive biopsies for routine clinical monitoring. We seek diagnostic partners to develop this as a commercial liquid biopsy kit.
39	Diagnostics	Antibody	<b>HD5 Diagnostic Kits: Precision Monitoring for Intestinal Health and Microbiome</b>	We established specialized mAbs for high-throughput quantification of Human $\alpha$ -Defensin 5 (HD5), a critical biomarker for intestinal immunity. This tool enables accurate, rapid diagnosis and monitoring of inflammatory bowel diseases (IBD). We seek diagnostic partners for the commercial rollout of these clinical-grade detection kits.
40	Diagnostics	NGS	<b>Portable Parasite NGS: A Field-Ready Comprehensive Detection System</b>	This portable NGS method identifies known and unknown parasites by amplifying long sequences while suppressing host DNA background. It is an essential tool for rapid diagnostics in resource-limited or outbreak-prone regions. We seek partners for field-testing and global deployment of this infectious disease surveillance technology.
41	Diagnostics / Research Tools	Assay / Detection Method	<b>Ultra-Sensitive Immunoassay Platform Using Advanced Optical Sensing</b>	We have developed a proprietary immunoassay platform enabling ultra-high sensitivity detection of protein biomarkers through advanced optical sensing. The technology significantly reduces background interference and achieves sensitivity well beyond conventional immunoassays, making it suitable for early disease detection and biomarker research. We seek partners in diagnostics and life science tools.
42	Pneumonia	Medical device	<b>Non-Invasive taVNS Device: A Neuromodulation Strategy for Interstitial Pneumonia</b>	This medical device provides taVNS therapy to modulate systemic inflammatory pathways, improving symptoms of interstitial pneumonia. As a side-effect-free adjunct to drug therapy, it offers a safe management tool for chronic lung diseases. We seek medtech partners for clinical trials and device commercialization.
43	Orthopedic Implant	Polymeric Material	<b>Biomimetic Artificial Cartilage Implant for Durable Joint Repair</b>	Our artificial cartilage implant mimics the mechanical properties of native cartilage while providing high durability and load-bearing capacity and lubricity. This off-the-shelf implant offers immediate structural support and is designed for the treatment of focal cartilage defects and early-stage osteoarthritis.
44	Liquid Embolic	Polymeric Material	<b>Cation-<math>\pi</math> Polymer Embolic Agent: Safe, Injectable, and Stable Vessel Occlusion</b>	Our proprietary liquid embolic agent uses a water soluble cation- $\pi$ copolymer that rapidly forms a thrombus-like gel via electrostatic interactions with blood components, enabling reliable vessel occlusion. Designed for smooth syringe/catheter delivery with minimal catheter tip adhesion, it supports safer, more controlled embolization.
45	Bio-imaging	Microscope Attachment	<b>Attachment for Microscope Objective Lenses and Microscope</b>	We have developed an innovative attachment for microscope objective lenses that enables precise microscopic spectroscopy during electromagnetic wave application. This technology ensures rapid, reproducible positioning of the application antenna, significantly boosting detection sensitivity and measurement accuracy. We seek medtech or diagnostic instrument partners to license this versatile hardware solution for advanced biological imaging and pharmaceutical analysis applications.